Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Go back to Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 72.72 -1.23 (1.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $73.95 | 52 Week High | $13.18 | |||
| Open | $73.04 | 52 Week Low | $6.00 | |||
| Day High | $74.01 | P/E | N/A | |||
| Day Low | $72.26 | EPS | $-1.24 | |||
| Volume | 1,140,925 | |||||
